803 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer

803 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer

Bibliographic Details
Main Authors:	Philip D Greenberg, Valentin Voillet, Raphael Gottardo, Kristin G Anderson, Breanna M Bates, Madison G Burnett, Susan L Ruskin, Yapeng Su, Magdalia L Suarez Gutierrez
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy
by: Philip D Greenberg, et al.
Published: (2022-03-01)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
by: Praveen K. Bommareddy, et al.
Published: (2019-04-01)

616 CD47 blockade modulates immunosuppressive checkpoint molecules and cellular metabolism to sensitize triple-negative breast cancer tumors to immune checkpoint blockade therapy
by: Pierre Triozzi, et al.
Published: (2021-11-01)

Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
by: Simona Camorani, et al.
Published: (2020-09-01)

8.03 Physics III, Spring 2003
by: Mavalvala, Nergis, et al.
Published: (2023)

Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance
by: Hyungjoo Kim, et al.
Published: (2022-05-01)

IL-15 and N-803 for HIV Cure Approaches
by: J. Natalie Howard, et al.
Published: (2023-09-01)

تیمورلنک ومحنة دمشق 803ه/1401م
by: علاء القداوی
Published: (2003-06-01)

Biomimetic nanoprobe-augmented triple therapy with photothermal, sonodynamic and checkpoint blockade inhibits tumor growth and metastasis
by: Xiaohong Lin, et al.
Published: (2022-02-01)

Rethinking immune checkpoint blockade: ‘Beyond the T cell’
by: Xiuting Liu, et al.
Published: (2021-01-01)

CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
by: A. V. Bogolyubova, et al.
Published: (2015-10-01)

803 Plasmacytoid Dendritic Cells are Not Major Producers of Type 1 Interferons in Cutaneous Lupus
by: Victoria P Werth, et al.
Published: (2022-12-01)

MCT4 blockade increases the efficacy of immune checkpoint blockade
by: Christian Schmidl, et al.
Published: (2023-10-01)

Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells
by: Alyssa Vito, et al.
Published: (2021-07-01)

Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer
by: Bhavana Palakurthi, et al.
Published: (2023-04-01)

Immune-Checkpoint Blockade Therapy in Lymphoma
by: Ayumi Kuzume, et al.
Published: (2020-07-01)

L4 F803 (161-174) [fotograf udara]
by: Malaysia. Direktorat Pemetaan Negara
Published: (1989)

Predictors of responses to immune checkpoint blockade in advanced melanoma
by: N. Jacquelot, et al.
Published: (2017-09-01)

Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
by: Maureen L. Drakes, et al.
Published: (2020-11-01)

P8.03 ASSESSMENT OF CAROTID ELASTICITY IN EXERCISE: A REPRODUCIBILITY STUDY
by: E. Bianchini, et al.
Published: (2010-12-01)

Sustained SHIV reactivation by N-803 in ART-treated CD8-depleted macaques
by: J.B. McBrien, et al.
Published: (2019-07-01)

Therapeutic Potential of IL-15 and N-803 in HIV/SIV Infection
by: Olivia Harwood, et al.
Published: (2021-09-01)

6.803 / 6.833 The Human Intelligence Enterprise, Spring 2002
by: Winston, Patrick Henry
Published: (2020)

6.803 / 6.833 The Human Intelligence Enterprise, Spring 2006
by: Winston, Patrick Henry
Published: (2020)

Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection
by: Jan Christoph Banck, et al.
Published: (2021-03-01)

Acquired Resistance to Immune Checkpoint Blockade Therapies
by: Xianda Zhao, et al.
Published: (2020-05-01)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
by: Brian J. Ahn, et al.
Published: (2013-11-01)

Epigenetic checkpoint blockade: new booster for immunotherapy
by: Ziqiao Wang, et al.
Published: (2021-07-01)

Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle
by: Maria A.V. Marzolini, et al.
Published: (2015-03-01)

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
by: Lin AY, et al.
Published: (2022-02-01)

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
by: Pfirschke, Christina, et al.
Published: (2018)

Metabolomic adaptations and correlates of survival to immune checkpoint blockade
by: Haoxin Li, et al.
Published: (2019-09-01)

Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
by: Daniele Marinelli, et al.
Published: (2020-09-01)

Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy
by: Lara Heij, et al.
Published: (2023-03-01)

The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy
by: Bonnie L. Russell, et al.
Published: (2021-06-01)

Expression of Mitochondrial Transcripts in Gastric MGC803 Cell Line Subjected by Hypoxia
by: Chengbo HAN, et al.
Published: (2009-04-01)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
by: Jeffrey Huang, et al.
Published: (2017-09-01)

8.03: A Arte na Universidade, A Universidade na Arte
by: Marco Buti
Published: (2009-01-01)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
by: William L. Redmond, et al.
Published: (2023-02-01)

Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803.
by: McNeill, L, et al.
Published: (2002)